Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.42 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | TLR2 | O60603 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 7/20 | 0.34 |
| ▸ | CA2 | P00918 | 3/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA4 | P22748 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9340071 | 0.87 | EPHX1 (0.52) | MEN1KMT2AEPHX1HSP90AA1SMN1; SMN2 | |
| SCHEMBL19172873 | 0.86 | MEN1 (0.42) | MEN1KMT2ASMN1; SMN2LMNATLR2 | |
| SCHEMBL12339214 | 0.84 | ACHE (0.44) | MEN1KMT2ASMN1; SMN2LMNAACHE | |
| SCHEMBL4761785 | 0.84 | ACHE (0.44) | MEN1KMT2ASMN1; SMN2LMNAACHE | |
| SCHEMBL14873875 | 0.83 | EPHX1 (0.45) | MEN1KMT2AEPHX1HSP90AA1SMN1; SMN2 | |
| SCHEMBL20696333 | 0.83 | MEN1 (0.48) | MEN1KMT2AEPHX1HSP90AA1SMN1; SMN2 | |
| SCHEMBL18850698 | 0.83 | MEN1 (0.48) | MEN1KMT2AEPHX1HSP90AA1SMN1; SMN2 | |
| SCHEMBL9587591 | 0.83 | MEN1 (0.48) | MEN1KMT2AEPHX1HSP90AA1SMN1; SMN2 | |
| SCHEMBL9980552 | 0.83 | L3MBTL1 (0.43) | MEN1KMT2ASMN1; SMN2LMNATLR2 | |
| SCHEMBL25209078 | 0.82 | MEN1 (0.40) | MEN1KMT2ASMN1; SMN2LMNATLR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10336785-B2 | Methods for synthesizing nucleotide analogues with disulfide linkers | QIAGEN SCIENCES, LLC (US) | 2019-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10336785-B2 | Methods for synthesizing nucleotide analogues with disulfide linkers | RNGTT, NT5C3B, DUT | MEN1 2635/4885KMT2A 2734/4885EPHX1 1312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.